A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope
Laura A. VanBlargan(Washington University in St. Louis), Michael Diamond(Washington University in St. Louis), Amarendra Pegu(National Institutes of Health), Scott A. Handley(Washington University in St. Louis), Pavlo Gilchuk(AstraZeneca (Japan)), Zhuoming Liu(Washington University in St. Louis), Haiyan Zhao(Hubei University of Medicine), James E. Crowe(Vanderbilt University Medical Center), Adrian Creanga(National Institute of Allergy and Infectious Diseases), Rita E. Chen(Washington University in St. Louis), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Bradley Whitener(Washington University in St. Louis), Lindsay Droit(Washington University in St. Louis), Daved H. Fremont(Washington University in St. Louis), Sean P. J. Whelan(University of Pittsburgh Medical Center), Lucas J. Adams(Washington University in St. Louis), Saravanan Raju(Washington University in St. Louis), David Wang(Washington University in St. Louis), Brittany Smith(Oak Ridge Associated Universities), James Brett Case(Washington University in St. Louis), Ishmael D. Aziati(Washington University in St. Louis), Emma S. Winkler(Washington University in St. Louis), Adrianus C. M. Boon
Cited by 16
Related Papers
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
|Science|2003|2.6k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k